Lucid Diagnostics Inc - Asset Resilience Ratio
Lucid Diagnostics Inc (LUCD) has an Asset Resilience Ratio of 6.09% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Lucid Diagnostics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2022)
This chart shows how Lucid Diagnostics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Lucid Diagnostics Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Lucid Diagnostics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read LUCD liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.59 Million | 6.09% |
| Total Liquid Assets | $2.59 Million | 6.09% |
Asset Resilience Insights
- Limited Liquidity: Lucid Diagnostics Inc maintains only 6.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lucid Diagnostics Inc Industry Peers by Asset Resilience Ratio
Compare Lucid Diagnostics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Lucid Diagnostics Inc (2019–2022)
The table below shows the annual Asset Resilience Ratio data for Lucid Diagnostics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 4.09% | $1.33 Million | $32.51 Million | +2.20pp |
| 2021-12-31 | 1.89% | $1.12 Million | $59.00 Million | -3.48pp |
| 2020-12-31 | 5.38% | $118.00K | $2.19 Million | -6.05pp |
| 2019-12-31 | 11.42% | $118.09K | $1.03 Million | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more